Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
NewLimit has raised $435 million and accelerated its lead epigenetic reprogramming therapy into human trials next year—a timeline compressed from over a decade away due to unexpectedly compelling preclinical data in liver cells. The approach targets aging at the cellular level to restore function rather than halt time, positioning epigenetic intervention as a potential foundation for addressing multiple age-related diseases simultaneously.
Scribe Therapeutics has gained regulatory clearance to test STX-1150, a CRISPR-based therapy designed to suppress the PCSK9 gene in the liver and achieve durable LDL cholesterol reduction from a single treatment. This approach addresses a critical adherence gap: most people struggle to maintain lifelong cholesterol medication, creating a window of unprotected cardiovascular risk that conventional drugs fail to close.
The Thalion Initiative, a newly launched nonprofit backed by prominent geroscience advisors, aims to fund fundamental aging research across five interconnected areas with a decade-long strategic plan. The organization represents a deliberate pivot from fragmented funding models toward coordinated, long-term investigation of aging biology itself.
Mayrlife Medical Health Resort has developed a structured lifestyle integration program for individuals already using GLP-1 medications, combining personalized nutrition, movement conditioning, and recovery protocols to address the metabolic and compositional changes that occur during pharmacologically-assisted weight loss. The program targets a critical gap: sustaining weight loss outcomes and preserving lean mass after GLP-1 initiation, rather than treating medication use in isolation.
Junevity's siRNA therapeutic demonstrates the ability to restore dysregulated gene networks to baseline function in diabetic models, with durable target knockdown and no safety signals in preclinical studies. This represents a shift from symptomatic management toward correcting upstream transcriptional dysfunction that drives metabolic and neurodegenerative disease.
Plozasiran (REDEMPLO), an RNA interference therapy for familial chylomicronemia syndrome, has reached early commercial traction with approximately 180 patients treated and 83% median triglyceride reduction sustained over two years. This represents a distinct mechanistic approach to severe hypertriglyceridemia — addressing hepatic APOC3 production directly — with clinical efficacy and safety data that support its positioning as an alternative to competing inhibitors.
Lysoway Therapeutics received $3.4 million to develop oral TMEM175 agonists targeting lysosomal function in Parkinson's disease. The approach addresses a genetically-linked mechanism of neurodegeneration by modulating how cells clear and recycle damaged proteins—a process that deteriorates with age and cellular stress.
Elysium Health is launching a physician-led longevity care program combining personalized supplements, prescriptions, peptides, and clinical monitoring — signaling a broader industry shift from isolated consumer products toward integrated healthcare delivery models. The structural evolution reflects market maturation and consumer demand for coordinated interventions rather than fragmented wellness tools.
Jupiter Neurosciences has initiated Phase 2a enrollment for JOTROL, an oral resveratrol derivative designed to address underlying neurodegeneration in Parkinson's disease rather than manage symptoms alone. The formulation achieves nine-fold higher bioavailability than standard resveratrol and demonstrated measurable central nervous system penetration, potentially addressing the chronic inflammation and mitochondrial dysfunction that drive disease progression.
Regenerative medicine is advancing from theoretical to practical application in liver repair, with organoid technology and engineered tissues now enabling researchers to reconstruct damaged liver tissue and potentially restore function. This represents a fundamental shift from managing liver decline to actively rebuilding organ structure—a capability with significant implications for extending healthspan in aging populations.
Clinical translation of aging interventions has accelerated substantially, with multiple therapies targeting root causes of age-related disease now in or approaching human trials. The field demonstrates measurable progress across cardiovascular, neurological, immune, and metabolic pathways that directly address mechanisms of aging rather than symptomatic disease management.
Elysium has established a physician-led clinical program offering personalized supplement protocols, peptides, and vitamin injections alongside ongoing medical support across four therapeutic domains: aging, performance, detoxification, and metabolic health. The program represents a shift toward integrating translational research with direct patient care and clinical oversight.